Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Gates Foundation to invest $5M in malaria effort
May 2016
SHARING OPTIONS:

EMERYVILLE, Calif.—Industrial bioscience company Amyris Inc. has inked a stock purchase agreement with the Bill & Melinda Gates Foundation for a $5-million equity investment. Per the agreement, the Gates Foundation will purchase roughly $5 million of Amyris common stock at $1.14 per share, the average daily closing share price for the 20 days prior to the signing. The closing was expected to occur on or about April 29, subject to customary closing conditions. This investment will fund a program aimed at further reducing the cost of one of the world's leading malaria treatments, with a focus on the continued production of high-quality, secure supplies of artemisinic acid and amorphadiene to be converted to artemisinin for use in artemisinin combination therapies, which are recommended by the World Health Organization as the primary first-line treatment for malaria.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.